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functional class and hematocrit and a significant decrease in aortic periprosthetic
regurgitation.
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Background: Older patients (pts) with aortic valve stenosis suitable for transcatheter
aortic valve implantation (TAVI) have an increased operative risk due to advanced age
and co-morbidities. However current risk scores have been shown not to be the ideal tool
to predict postinterventional outcome in this population. Frailty especially seems to be one
of the major factors not included into these scores. Therefore aim of this study was to
elucidate whether frailty assessment helps to predict outcome after TAVI.
Methods: Pts were assessed prospectively regarding there over all appearance by two
independent physicians and a numerical score from 1 (frail)-10 (good condition) was
given. Additionally Katz activity score, gait speed testing, a five feet walk test and a hand
grip strength test were performed. After 30days follow-up hemodynamic, clinical data as
well as VARC safety endpoints were analysed.
Results: A total of 75pts (age 816years) with a logEuroSCORE of 20.612.7% were
treated. Almost ¾ of the pts received a Medtronic CoreValve and 19 an Edwards SAPIEN
XT, two of them as valve-in-valve. The prostheses were successfully implanted in all pts.
The mean gradient declined from 67.012.3 to 12.07.5mmHg. VARC success was
achieved in 97.3%. The combined safety endpoint occurred in 24%. One pt died due to
intracranial haemorrhage and one major stroke was noted. Thus major stroke and death
occurred in 2.67%. Mean appearance score was 6.31.7, mean Katz activity score
5.41.4. Mean time to overcome five-feet was measured 8.54.2s. Mean hand grip
strength of the dominant hand was 20.28.5Kg. There was no significant predictive value
of hand grip strength and Katz score using a regression analysis (p0.938; 0.925-1.089;
p0.301; 0.526-1.222). The reduced walking speed failed to reach the level of signifi-
cance in this relatively small cohort (p0.06; 0.991-1.529). Only the overall appearance
score had significant predictive value for the occurrence of the combined safety endpoint
(p0.015; 0.280-0.873).
Conclusions: TAVI in older pts with higher risk is safe, feasible and reliable. Frailty
assessment provides additional information but individual clinical judgment remains
crucial to insure beneficial outcome.
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Background: Valve-size selection for TAVI is based on annular measurements by
echocardiography or CT. Still, relevant PAR with negative impact on survival is
common(20%). We sought to evaluate whether supraaortic angiography during BAV may
provide improved sizing(figure).
Methods: Data of 167 consecutive pts with conventional sizing (echo,CT) (group 1) were
compared to 103 successive pts, in which BAV was, additionally leveraged for
size-selection (group 2). PAR was graded angiographically (Sellers criteria) and quanti-
tatively using the pressure difference between diastolic aortic pressure and LVEDP (P
DAP–LVEDP) and the myocardial supply-demand ratio (DPTI:SPTI), a P DAP–
LVEDP18 mmHg and a DPTI:SPTI0.7 having previously been proposed as cut-off
values associated with increased cardiovascular mortality.
Results: TAVI was successful in all pts (ES:166,MCV:103), PAR was observed in
113pts of gp1 and 41pts of gp2 (67vs40%, p0.05). At least Moderate PAR, a p
DAP–LVEDP18 mmHg and a DPTI:SPTI0.7 were observed more frequently in gp1
than gp2: 14.4vs7.8%, 26.3vs14.5% and 11.9vs6.7% (p0.05). According to preinter-
ventional imaging, 40pts had a borderline annulus size, raising uncertainty regarding
valve-size selection. Balloon-sizing resulted in selection of the “bigger” prosthesis in
21pts; only 2 of these pts had relevant PAR. Cardiovascular mortality at 30 days&1-year
was significantly decreased in gp2 compared to gp1 (5.8vs9% & 10.6vs20%, p0.05).(no
BAV-complications).
Conclusions: Preparatory BAV during TAVI can be leveraged to improve valve-size
selection and reduce associated PAR, especially in borderline cases.
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Background: TAVI is currently transforming the treatment of non-operable and
high-risk pts. with aortic stenosis, and the randomized PARTNER trial has shown
excellent results. Notably, several pts. with comorbid conditions, which are frequently
encountered in a real-world setting, were excluded. However, such pts. are already treated
in countries with CE-approval. We report our two-center transfemoral (TF) TAVI-
experience with focus on the comparison between real-world and PARTNER-like
patients.
Methods: Over 6 years (2006-11) 485 pts. (age: 807;EuroSCORE: 2216%) under-
went TF TAVI (ES 176; MCV 309). Patients were divided into a “PARTNER-like” and
a “PARTNER-exclusion” group based on PARTNER B inclusion criteria. Differences in
30-day, 1- and 2-year mortality were assessed.
Results: 213 pts. would have been excluded from PARTNER B, most frequent exclusion
criteria being prior valve surgery (16%), chronic renal failure (14%), severe mitral
regurgitation (11%), reduced LV-EF (9%) and prior PCI (6%). Pts. in the “PARTNER-
exclusion” group had a higher 1- and 2-year mortality than in the “PARTNER-like”
group, and a non-significant trend towards an increased 30-day mortality. Compared to
PARTNER-data, “PARTNER-like” pts. had a slightly higher 30-day, but a markedly
lower 2-year mortality. Interestingly, 2-year mortality was also lower in excluded pts.
despite a two-fold 30-day mortality.
Conclusions: In our real-world experience, 44% of TAVI pts. did not meet PARTNER
inclusion criteria. Although these pts. had a comparatively high early hazard, the late
outcome benefit was, interestingly, better than reported for PARTNER.
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Background: TAVI is currently performed with excellent results by dedicated, multi-
disciplinary heart teams at highly specialized centers. In the real-world, a substantial
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